Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine the safety and outcome (long-term control) of a
high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem
cells from a partially matched adult family member donor, called haploidentical stem cell
transplantation, in high-risk sickle cell disease patients.
Funding Source - FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Collaborators:
Ann & Robert H Lurie Children's Hospital of Chicago Ann and Robert H. Lurie Children's Hospital of Chicago Children's Hospital & Research Center Oakland Children's Hospital Medical Center, Cincinnati Medical College of Wisconsin Miltenyi Biomedicine GmbH Miltenyi Biotec GmbH Tufts Medical Center UCSF Benioff Children's Hospital Oakland University of California, Los Angeles University of California, San Francisco Washington University School of Medicine